Alexion Pharmaceuticals said in a regulatory filing Wednesday it is nearing a $25 million settlement with the Securities and Exchange Commission concerning an investigation into the company’s compliance with the Foreign Corrupt Practices Act spanning various countries.
As previously disclosed, Alexion first received a subpoena in May 2015 concerning an investigation by the SEC’s Enforcement Division “requesting information related to our grant-making activities and compliance with the FCPA in various countries.” Additionally, Alexion received a request from the Department of Justice in October 2015 “for the voluntary production of documents and other information pertaining to Alexion’s compliance with the FCPA.”
